7,560 Shares in Simulations Plus, Inc. (NASDAQ:SLP) Purchased by Olympiad Research LP

Olympiad Research LP bought a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,560 shares of the technology company’s stock, valued at approximately $211,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. First Horizon Advisors Inc. raised its stake in Simulations Plus by 82.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after purchasing an additional 370 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Simulations Plus in the 3rd quarter worth about $59,000. US Bancorp DE raised its stake in Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after purchasing an additional 1,343 shares in the last quarter. Pitcairn Co. raised its stake in Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock worth $211,000 after purchasing an additional 549 shares in the last quarter. Finally, First National Bank of Omaha raised its stake in Simulations Plus by 56.1% in the 3rd quarter. First National Bank of Omaha now owns 9,704 shares of the technology company’s stock worth $311,000 after purchasing an additional 3,488 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 19.40% of the stock is owned by corporate insiders.

Simulations Plus Trading Down 0.2 %

Shares of NASDAQ:SLP opened at $31.77 on Monday. The firm has a 50 day moving average of $31.71 and a 200-day moving average of $32.09. The stock has a market capitalization of $638.32 million, a PE ratio of 79.43 and a beta of 0.83. Simulations Plus, Inc. has a 12 month low of $24.00 and a 12 month high of $51.22.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SLP. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Stephens began coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective for the company. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, KeyCorp boosted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.